These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 35481118)

  • 1. Comparative risk of musculoskeletal adverse reactions among new users of dipeptidyl peptidase-4 inhibitors: A retrospective cohort study.
    Park T; Bresnahan M; Griggs SK; Chen J; Cho AH; Gousse Y; Feinglos M
    Explor Res Clin Soc Pharm; 2021 Jun; 2():100022. PubMed ID: 35481118
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative effectiveness of incretin-based therapies and the risk of death and cardiovascular events in 38,233 metformin monotherapy users.
    Gamble JM; Thomas JM; Twells LK; Midodzi WK; Majumdar SR
    Medicine (Baltimore); 2016 Jun; 95(26):e3995. PubMed ID: 27368005
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risks of cardiovascular diseases associated with dipeptidyl peptidase-4 inhibitors and other antidiabetic drugs in patients with type 2 diabetes: a nation-wide longitudinal study.
    Ou HT; Chang KC; Li CY; Wu JS
    Cardiovasc Diabetol; 2016 Mar; 15():41. PubMed ID: 26932742
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dipeptidyl peptidase-4 inhibitors lower the risk of autoimmune disease in patients with type 2 diabetes mellitus: A nationwide population-based cohort study.
    Seong JM; Yee J; Gwak HS
    Br J Clin Pharmacol; 2019 Aug; 85(8):1719-1727. PubMed ID: 30964554
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association Between DPP4 Inhibitor Use and the Incidence of Cirrhosis, ESRD, and Some Cancers in Patients With Diabetes.
    Na Y; Kim SW; Park IB; Choi SJ; Nam S; Jung J; Lee DH
    J Clin Endocrinol Metab; 2022 Nov; 107(11):3022-3034. PubMed ID: 36108097
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dipeptidyl peptidase-4 inhibitors in type 2 diabetes may reduce the risk of autoimmune diseases: a population-based cohort study.
    Kim SC; Schneeweiss S; Glynn RJ; Doherty M; Goldfine AB; Solomon DH
    Ann Rheum Dis; 2015 Nov; 74(11):1968-75. PubMed ID: 24919467
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Major adverse cardiovascular and limb events in patients with diabetes treated with GLP-1 receptor agonists vs DPP-4 inhibitors.
    Lin DS; Lee JK; Chen WJ
    Diabetologia; 2021 Sep; 64(9):1949-1962. PubMed ID: 34195865
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of sodium-glucose cotransporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors on diabetic retinopathy and its progression: A real-world Korean study.
    Chung YR; Ha KH; Lee K; Kim DJ
    PLoS One; 2019; 14(10):e0224549. PubMed ID: 31658289
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dipeptidyl peptidase-4 inhibitors do not increase the risk of cardiovascular events in type 2 diabetes: a cohort study.
    Kim SC; Glynn RJ; Liu J; Everett BM; Goldfine AB
    Acta Diabetol; 2014 Dec; 51(6):1015-23. PubMed ID: 25311055
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intensification with dipeptidyl peptidase-4 inhibitor, insulin, or thiazolidinediones and risks of all-cause mortality, cardiovascular diseases, and severe hypoglycemia in patients on metformin-sulfonylurea dual therapy: A retrospective cohort study.
    Wong CKH; Man KKC; Shi M; Chan EW; Ho CW; Tse ETY; Wong ICK; Lam CLK
    PLoS Med; 2019 Dec; 16(12):e1002999. PubMed ID: 31877127
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative cardiovascular risks of dipeptidyl peptidase 4 inhibitors with other second- and third-line antidiabetic drugs in patients with type 2 diabetes.
    Ou HT; Chang KC; Li CY; Wu JS
    Br J Clin Pharmacol; 2017 Jul; 83(7):1556-1570. PubMed ID: 28109184
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of Dipeptidyl-Peptidase-4 Inhibitors and the Risk of Pneumonia: A Population-Based Cohort Study.
    Wvan der Zanden R; de Vries F; Lalmohamed A; Driessen JH; de Boer A; Rohde G; Neef C; den Heijer C
    PLoS One; 2015; 10(10):e0139367. PubMed ID: 26468883
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative Safety of Dipeptidyl Peptidase-4 Inhibitors Versus Sulfonylureas and Other Glucose-lowering Therapies for Three Acute Outcomes.
    Gamble JM; Donnan JR; Chibrikov E; Twells LK; Midodzi WK; Majumdar SR
    Sci Rep; 2018 Oct; 8(1):15142. PubMed ID: 30310100
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glucagon-Like Peptide-1 Receptor Agonists and Hepatic Decompensation Events in Patients With Cirrhosis and Diabetes.
    Simon TG; Patorno E; Schneeweiss S
    Clin Gastroenterol Hepatol; 2022 Jun; 20(6):1382-1393.e19. PubMed ID: 34256144
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dipeptidyl-Peptidase 4 Inhibitors did not Improve Renal Endpoints in Advanced Diabetic Kidney Disease.
    Kornelius E; Huang CN; Lo SC; Wang YH; Yang YS
    Endocr Pract; 2020 Dec; 26(12):1486-1496. PubMed ID: 33471741
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of dipeptidyl peptidase-4 inhibitor treatment doses on tuberculosis in patients with diabetes: a long-term nationwide population-based cohort study.
    Chen HH; Hsieh MC; Ho CW; Chen CC; Hsu SP; Lin CL; Kao CH
    Ann Palliat Med; 2020 Sep; 9(5):2817-2825. PubMed ID: 32787376
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DPP4i, thiazolidinediones, or insulin and risks of cancer in patients with type 2 diabetes mellitus on metformin-sulfonylurea dual therapy with inadequate control.
    Wong CKH; Man KKC; Chan EWY; Wu T; Tse ETY; Wong ICK; Lam CLK
    BMJ Open Diabetes Res Care; 2020 Jun; 8(1):. PubMed ID: 32532851
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dipeptidyl peptidase-4 inhibitor use is not associated with elevated risk of severe joint pain in patients with type 2 diabetes: a population-based cohort study.
    Hou WH; Chang KC; Li CY; Ou HT
    Pain; 2016 Sep; 157(9):1954-1959. PubMed ID: 27127847
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The association of dipeptidyl peptidase IV inhibitors and other risk factors with bullous pemphigoid in patients with type 2 diabetes mellitus: A retrospective cohort study.
    Guo JY; Chen HH; Yang YC; Wu PY; Chang MP; Chen CC
    J Diabetes Complications; 2020 Mar; 34(3):107515. PubMed ID: 31932172
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardioprotective effects of dipeptidyl peptidase-4 inhibitors versus sulfonylureas in addition to metformin: A nationwide cohort study of patients with type 2 diabetes.
    Wang J; Wu HY; Chien KL
    Diabetes Metab; 2022 May; 48(3):101299. PubMed ID: 34728339
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.